Gain Therapeutics Inc.

NASDAQ: GANX · Real-Time Price · USD
1.73
0.19 (12.34%)
At close: Aug 15, 2025, 3:59 PM
1.76
1.73%
After-hours: Aug 15, 2025, 07:49 PM EDT

Gain Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
82.24K 82.24K 82.24K 64.8K 64.8K 64.8K 119.98K 195.29K 195.29K 290.39K 280.22K 176.45K 203.79K 197.87K 158.13K 130.93K 110.28K 27.48K
Cost of Revenue
63.61K 84.2K 84.07K 86.35K 85.22K 64.63K 44.1K 38.62K 18.11K 36.35K 44.56K 26.45K 26.45K 8.21K n/a 975.61K 1.4M 1.84M
Gross Profit
-63.61K -84.2K -84.07K -86.35K -85.22K -84.86K -64.34K 81.25K 82.15K 179.25K 216.05K -1.34M -3.77M -5.55M -7.01M -6.54M -4.51M -3.24M
Operating Income
-17.25M -20.34M -20.35M -21.43M -21.85M -21.4M -22.25M -22.41M -22.27M -19.72M -17.78M -16.42M -16.31M -14.65M -13.83M -12.23M -8.42M -5.43M
Interest Income
240.24K 282.21K 357.1K 411.51K 412.1K 457.5K 342.2K 235.93K 129.93K 59.9K 59.9K 59.9K 59.9K n/a n/a n/a n/a n/a
Pretax Income
-17.84M -20.31M -19.87M -21.32M -21.54M -21.06M -22.19M -22.08M -21.93M -19.35M -17.5M -16.13M -16.23M -14.71M -13.89M -12.32M -8.45M -5.44M
Net Income
-18.59M -20.93M -20.41M -21.37M -21.6M -21.14M -22.27M -22.22M -22.06M -19.46M -17.59M -16.14M -16.24M -14.71M -13.89M -12.33M -8.46M -5.44M
Selling & General & Admin
8.39M 9.8M 9.55M 9.46M 10.14M 10.14M 10.77M 11.04M 11.31M 10.26M 9.54M 9.03M 8.43M 7.55M 6.83M 5.7M 3.91M 2.2M
Research & Development
8.85M 10.53M 10.77M 11.92M 11.67M 11.22M 11.51M 11.42M 11.02M 9.61M 8.38M 7.58M 8.09M 7.3M 7.16M 6.67M 4.62M 3.26M
Other Expenses
-11.31K -11.31K -11.31K n/a n/a n/a n/a n/a n/a n/a n/a 18.93K 7.56K n/a n/a -18.93K -14.25K -13.07K
Operating Expenses
17.23M 20.32M 20.31M 21.38M 21.81M 21.36M 22.28M 22.46M 22.33M 19.87M 17.92M 16.6M 16.51M 14.85M 13.98M 12.36M 8.09M 4.58M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.65K 1.65K 1.65K 1.65K n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a -12.53K -27.29K -27.29K -27.29K -14.77K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
17.25M 20.34M 20.35M 21.43M 21.85M 21.4M 22.31M 22.46M 22.33M 19.87M 17.92M 16.6M 16.51M 14.85M 13.98M 12.36M 8.53M 5.46M
Income Tax Expense
757.45K 617.45K 536.82K 46.58K 57.04K 82.42K 79.28K 142.88K 125.47K 108.03K 92.98K 6.63K 7.69K 2.21K 4.01K 10.88K 6.66K 7.52K
Shares Outstanding (Basic)
30.34M 28.69M 27.13M 26.53M 19.22M 17.98M 16.21M 12.7M 12.39M 11.94M 11.88M 11.88M 11.83M 11.88M 10.17M 11.88M 11.88M 11.6M
Shares Outstanding (Diluted)
30.34M 28.69M 27.13M 26.53M 19.22M 17.98M 16.21M 12.7M 12.39M 11.94M 11.88M 11.88M 11.88M 11.88M 10.17M 11.88M 11.88M 11.6M
EPS (Basic)
-0.66 -0.89 -0.95 -1.1 -1.3 -1.5 -1.71 -1.81 -1.82 -1.63 -1.48 -1.41 -1.42 -1.29 -1.22 -1.05 -0.74 -0.49
EPS (Diluted)
-0.66 -0.89 -0.95 -1.1 -1.3 -1.5 -1.71 -1.81 -1.82 -1.63 -1.48 -1.41 -1.42 -1.29 -1.22 -1.05 -0.74 -0.49
EBITDA
-17.21M -20.28M -20.28M -21.37M -21.81M -21.37M -22.21M -22.36M -22.23M -19.68M -17.75M -16.42M -16.28M -14.61M -13.79M -12.19M -8.41M -5.42M
EBIT
-17.83M -20.34M -20.35M -21.43M -21.85M -21.4M -22.25M -22.41M -22.27M -19.72M -17.78M -16.42M -16.31M -14.65M -13.83M -12.23M -8.42M -5.43M
Depreciation & Amortization
63.61K 84.2K 84.07K 86.35K 85.22K 84.86K 83.58K 78.1K 77.2K 75.2K 64.17K 51.85K 86.51K 70.42K 65.61K 62.66K 10.78K 10.89K